Estimation of serum complement levels in chronic spontaneous urticaria as a novel disease marker and its correlation with the disease severity
Not Applicable
- Conditions
- Health Condition 1: L509- Urticaria, unspecified
- Registration Number
- CTRI/2023/08/056718
- Lead Sponsor
- Father Muller research centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Non-smokers
Patients diagnosed with active chronic spontaneous urticaria of more than or equal to 6 weeks duration.
Exclusion Criteria
1.The subjects should not have taken oral corticosteroids or other immunosuppressive drugs in the last 8 weeks or antihistamines at least within 4 days before the day of assessment.
2.Patients with known complement deficiencies, recent trauma ( <12 hours of injury), acute infection, immune complex disease, and other autoimmune diseases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method With this study, we may be able to indicate the role of complement proteins, C3 & C4 in the pathogenesis of CSU & assess its role in the prognosis of the disease severity. <br/ ><br>The knowledge derived from this study can help us develop a treatment system that caters to the severity of the disease process & further develop newer treatment options targeting C3, C4, which could be a promising option for the treatment of CSU. <br/ ><br>Timepoint: one year
- Secondary Outcome Measures
Name Time Method The knowledge derived from this study can help us develop a treatment system that caters to the severity of the disease process & further develop newer treatment options targeting C3, C4, which could be a promising option for the treatment of CSU.Timepoint: 10 years